Not independent
Tenure on this board
1.8 yrs
Also a director at
Edwards Lifesciences Corp (EW)
6 nominees · 5 ballot items.
Election of six directors; ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2025; advisory vote on the compensation of Pulse Biosciences, Inc.'s named executive officers; advisory vote on the frequency of future advisory stockholder votes to approve executive compensation; and such other business as may properly come before the Annual Meeting.
Elect six nominees to serve on Pulse Biosciences’ Board of Directors for one-year terms expiring at the 2026 annual meeting of stockholders.
Ratify Deloitte & Touche LLP as Pulse Biosciences’ independent registered public accounting firm for the fiscal year ending December 31, 2025.
Approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the fiscal year ending December 31, 2024.
Vote on how frequently Pulse Biosciences should solicit advisory stockholder approval of executive compensation (every year, every 2 years, or every 3 years).
Transact such other business as may properly come before the Annual Meeting.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 1.3% | 866,061 | $19M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2% | 815,852 | $18M |
| 3 | Portolan Capital Management, LLC | 1.1% | 733,372 | $16M |
| 4 | BlackRock, Inc. | 1.0% | 683,017 | $15M |
| 5 | BlackRock, Inc. | 0.7% | 493,117 | $11M |
| 6 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.7% | 462,899 | $10M |
| 7 | STATE STREET CORP | 0.7% | 456,927 | $10M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.6% | 428,167 | $9M |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 0.4% | 265,164 | $6M |
| 10 | GRIFFIN ASSET MANAGEMENT, INC. | 0.3% | 225,177 | $5M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.